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Background: Factor XIII (FXIII), a plasma pro-transglutaminase, consists of two A subunits and two B subunits
(FXIIIA2B2). Following activation by thrombin, it cross-links ﬁbrin chains at the ﬁnal step of coagulation. We
previously reported that FXIII subunit A (FXIIIA) serves as a protein disulﬁde isomerase (PDI), and that PDI
promotes platelet adhesion and aggregation.
Objective: This study sought to examine possible mechanistic effect of FXIII on platelet adhesion to ﬁbrinogen;
speciﬁcally, the role of its PDI activity.
Methods: Ex vivo experiments: Blood platelets derived from ﬁve patients with hereditary FXIIIA deﬁciency before
and after treatment with Fibrogammin-P (FXIIIA2B2 concentrate) were washed and incubated on immobilized
ﬁbrinogen. Bound platelets were stained and counted by microscopy. In vitro experiments: Platelets derived
from patients before treatment and ﬁve healthy controls were washed and analyzed for adhesion in the pres-
ence or absence of Fibrogammin-P or recombinant FXIII (FXIIIA2 concentrate).
Results: In ex vivo experiments, one hour after Fibrogammin-P treatment,mean (±SEM)platelet adhesion toﬁbrin-
ogen increased by 27±2.32% (pb0.001). In in vitro experiments, treatment with Fibrogammin-P or recombinant
FXIII (10 IU/mL each) enhanced platelet adhesion to ﬁbrinogen (in patients, by 29.95±6.7% and 29.05±5.3%,
respectively; in controls, by 26.06±3.24% and 26.91±4.72, respectively; pb0.04 for all). Iodoacetamide-treated
FXIII (I-FXIII), where transglutaminase activity is blocked, showed similar enhanced adhesion as untreated FXIII.
By contrast, addition of an antibody that speciﬁcally blocks FXIIIA-PDI activity inhibited FXIII-mediated platelet
adhesion to ﬁbrinogen by 65%.
Conclusion: These ﬁndings indicate that FXIII-induced enhancement of platelet adhesion is mediated by FXIII-PDI
activity.© 2012 Elsevier Ltd. All rights reserved.Introduction
Coagulation factor XIII (FXIII) is a plasma pro-transglutaminase.
Following activation by thrombin, it cross-links ﬁbrin chains at the
ﬁnal step of coagulation to form a soluble clot [1]. FXIII circulates in
plasma as a heterotetramer of two A subunits (FXIIIA2 - the active
transglutaminase) and two B subunits (FXIIIB2 – the carrier protein)
[1]. Besides its role in hemostasis, FXIII accelerates wound healing
[2], probably by its pro-angiogenic effects [3] as well as by stimulation
of monocytes and ﬁbroblasts [4]. Several new lines of evidence pointIII, recombinant FXIII; I-FXIII,
XIII; PRP, platelet-rich plasma.
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rights reserved.to the involvement of FXIII in platelet function aswell [5–8]. FXIII subunit
A (FXIIIA)was detected on thrombin-receptor-activated platelets [5], and
platelets were found to adhere to FXIII-covered surface [6]; this interac-
tion depended on the intact ﬁbrinogen binding to integrin αIIbβ3 [5,6].
Accordingly, no clot retraction was noted in FXIIIA knock-out mice [7],
and patientswith FXIII deﬁciency, a rare hereditary life-long bleeding dis-
order [8], showed reduced ﬁbrinogen binding to thrombin-stimulated
platelets and reduced platelet adhesion to ﬁbrinogen-covered surface [9].
We recently reported that FXIIIA has protein disulﬁde isomerase
(PDI) activity, independent of its transglutaminase activity [10]. Cell-
surface-localized, membrane-bound PDI is essential for sustaining the
binding of ﬁbrinogen, ﬁbronectin, and collagen to platelet integrins
αIIbβ3,α5β1, and α2β1, respectively [11,12], thereby regulating plate-
let adhesion [11,12] and aggregation [13]. PDI also regulates the activity
of L-selectin, a cell-adhesion molecule found on leukocytes [14]. Specif-
ically, it was found to mediate the entry of human immunodeﬁciency
virus into lymphocytes [15] and the entry of nitric oxide into cells [16].
339J. Lahav et al. / Thrombosis Research 131 (2013) 338–341In the present study, on the basis of our earlier ﬁndings that PDI
plays a mediatory role in platelet adhesion [11–13] and that FXIIIA
exerts PDI activity [10], we sought to examine the relative contribu-




Fibrogammin-P (FXIIIA2B2 concentrate) was purchased from
ZLB-Behring, Marburg, Germany. Recombinant FXIII (rFXIII) was a gift
from Novo Nordisk, Bagsvaerd, Denmark. Puriﬁed FXIII, used to test
the inhibitory effect of anti-FXIII antibody, was described previously
[10]. Rabbit anti-human factor XIII A-subunit antiserum, (Assera XIII
A), was purchased from Diagnostica Stago, Asnieres sur Seine, France.
Sheep anti-human factor XIIIA2B2 (SAXIII-IG) was purchased from Af-
ﬁnity Biologicals Inc. Normal rabbit serum and an irrelevant antiserum
raised in rabbit (antibiotin), were purchased from Sigma, Israel.
To prepare iodoacetamide-treated FXIII (I-FXIII), approximately
100 IU/ml reconstituted Fibrogammin P was activated by thrombin
immobilized on Afﬁ-gel-10 beads (Bio-Rad Laboratories, Hercules, CA,
USA), as described previously [4]. To generate FXIII with blocked
transglutaminase activity (I-FXIII) the thrombin-activated Fibrogammin-P
(FXIIIa) was inactivated by treatment with 3 mM iodoacetamide for
30 minutes at 22 °C. Free iodoacetamide was removed by dialysis.
Patients and Controls
Five patients with hereditary FXIIIA deﬁciency and ﬁve healthy con-
trol subjects were studied. None of the control subjects tookmedication
affecting platelet function for two weeks prior to the study. The criteria
for diagnosis of FXIIIA deﬁciency as well as the genotype of the patients
were published previously [16,17]. The patients were being treated on a
prophylactic basis with 20 IU/kg of Fibrogammin-P every 4 weeks.
Study Design
The study was divided into two parts. For the ex vivo experiments,
we used platelets from blood samples drawn from each patient before
and one hour after treatment. For the in vitro experiments, we used
platelets from blood samples drawn from the patients before treat-
ment and from the control subjects. The study was approved by the
Hospital Ethics Committee and informed consent was obtained from
each participant.
Preparation of Platelet-rich Plasma (PRP) and Washed Platelets
Venous blood from patients and controls was drawn from the
antecubital vein following loose application of a tourniquet. The blood
was anticoagulated with trisodium citrate (0.0108 M) and processed
within 1 hour of collection. PRP was prepared by centrifugation at
700 rpm for 15 min. Washed platelets were prepared as previously de-
scribed [12]. Brieﬂy 1/10 volume of CTADX10 (citric acid 0.11 M, the-
ophylline 15 mM, adenosine 3.7 mM, and dipyridamole 0.198 mM at
pH 5.0) was added to the PRP followed by centrifugation at 2000 rpm
for 10 min. The platelet precipitatewas resuspended in saline containing
ACD (citric acid 71 mM, sodium citrate 0.085 mM, D-glucose 11 mM),
centrifuged, and resuspended in adhesion buffer (NaCO3 12 mM, NaCl
138 mM, D-glucose 5.5 mM, KCl 2.9 mM, HEPES 50 mM, CaCl2 1 mM,
MgCl2 2 mM, pH 7.2).
Platelet Adhesion to Protein-covered Plastic
For the ex vivo experiments, thewashed platelets from blood drawn
before and one hour after infusion of 20 IU/kg Fibrogammin-P wereincubated on ﬁbrinogen-covered substrata. Adhesion was quantitated
by counting the bound cells under light microscopy, as previously de-
scribed [18]. For the in vitro experiments, the washed platelets from
the healthy controls and patients before treatment were analyzed for
adhesion in the presence or absence of 10 IU/mL Fibrogammin-P, or
I-FXIII, or rFXIII . In some experiments, antibodies were added 20 min
prior to adhesion at a 1:20 ﬁnal dilution. In these experiments, PDI-
inhibiting rabbit anti-FXIIIA antibody, sheep anti FXIIIA2B2 antibody
with no inhibitory effect on PDI activity, normal rabbit serum and an
irrelevant antiserum raised in rabbit were used at the same dilution as
controls. Adhesion was quantitated as previously described [18].
Effect of Anti-FXIIIA Antibodies on Transglutaminase or PDI Activity of
FXIII
Highly puriﬁed human plasma-derived FXIIIA2B2 was prepared
from the pooled plasma of healthy volunteers and thrombin-activated
(FXIIIa) according to the procedure of Lorand et al. [19]. In brief,
50 μg/ml (2.4 U/ml) FXIIIA2B2 in 50 mM HEPES, 100 mM NaCl, and
5 mM CaCl2 at pH 7.4 was activated by 20 U/ml human thrombin for
5 min at 37 °C; thrombin was then blocked by 30 U/ml hirudin
(Sigma-Aldrich, St. Louis, MO). FXIIIa was incubated with an equal vol-
ume of different antibody dilutions or HEPES-NaCl buffer for 30 min at
37 °C. Its transglutaminase activity wasmeasured by the spectrophoto-
metric method of Kárpáti et al. [20]. The results were expressed as a
percentage of FXIIIa activity in the absence of antibody dilution.
PDI activity was determined by measuring the ability to restore
RNase activity of rdRNase as previously described (10). FXIIIA2B2 was
incubated with equal volume of different antibody dilutions or HEPES-
NaCl buffer for 30 min at 37 °C and PDI activity of FXIII was measured
as above.
Statistical Analysis
T-test was used to compare mean (±SEM) platelet adhesion be-
fore and after treatment with FXIII concentrate and to compare
mean (±SEM) platelet adhesion in the presence or absence of differ-
ent FXIII preparations. Pb0.05 was considered signiﬁcant.
Results
The ex vivo ﬁndings shown in Fig. 1 represent the summation of
56 treatments in ﬁve patients with hereditary FXIIIA deﬁciency. One
hour after Fibrogammin-P infusion, platelet adhesion to ﬁbrinogen
increased by a 27±2.32% from the pretreatment level (pb0.001).
Results of the in vitro experiments are presented in Fig. 2. The ad-
dition of Fibrogammin-P (10 IU/mL) to the washed platelets from the
patients enhanced adhesion to ﬁbrinogen by 29.95±6.7%, and the
addition of rFXIII (10 1U/mL) enhanced adhesion by 29.05±5.3%
(n≥20, pb0.04 for each). Similar results were obtained with washed
control platelets (26.06±3.24% and 26.91±4.72%, respectively,
n≥10; pb0.04 for each) (Fig. 2).
To distinguish between the transglutaminase and PDI activity of
FXIII, we used a speciﬁc rabbit anti-FXIIIA antibody which inhibited
PDI activity in our previous study [10]. The addition of anti-FXIIIA anti-
body (at a dilution of 1:20) to plasma-puriﬁed FXIII inhibited 75% of
FXIIIA PDI activity without inhibiting transglutaminase activity (Fig. 3).
The comparison of the effect of Fibrogammin-P alone to that of
anti-FXIIIA antibody+Fibrogammin-P on patients' platelet adhesion
is shown in Fig. 4. Relative to the untreated platelets, the addition of
Fibrogammin-P enhanced platelet adhesion to ﬁbrinogen by approx-
imately 30%. The combination of rabbit anti-human FXIIIA antibody
known to inhibit PDI activity [10] with Fibrogammin-P resulted in a
65% reduction in adhesion (Fig. 4; n=10; pb0.001), which is beyond
the expected 30% inhibition of the effect of Fibrogammin (n=10,
pb0.05; Fig. 4). This ﬁnding may indicate that this anti-FXIIIA
Fig. 1. Fibrinogen adhesion of platelets derived from patients with hereditary FXIIIA deﬁ-
ciency before and after treatment with Fibrogammin-P. Washed platelets were prepared
from patients' PRP before and one hour after infusion of 20 IU/kg Fibrogammin and incu-
bated on ﬁbrinogen-covered surface. Bound platelets were counted by microscopy. The
results are expressed as mean±SEM percent increase in adhesion of 56 treatments.
Each experiment during one treatment was done in quadruplicate.
Fig. 3. Anti-FXIII antibody inhibition of FXIII-PDI activity but not FXIII - transglutaminase
activity. Serial dilutions of anti-human factor XIII A-subunit antibodywere incubatedwith
plasma-puriﬁed FXIII and either transglutaminase or PDI activity was determined. Results
are expressed as mean±SEM (n=3).
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of this antibody to untreated platelets inhibited 36±11.6% of platelet
adhesion to ﬁbrinogen (pb0.01; data not shown). By contrast to the
rabbit anti-FXIIIA antibody we found that the sheep anti-FXIII A2B2
antibody showed no inhibition of PDI activity. Addition of this sheep
anti-human FXIIIA2B2 antibody, had no effect on Fibrogammin-
P-mediated enhancement of platelet adhesion: 26%±18% increase
in adhesion in the presence and 22%±9% increase in adhesion in
the absence of the antibody (p=0.6).
Incubation of the patients' platelets with I-FXIII (10 IU/ml), in which
transglutaminase activity is blocked by iodoacetamide, increased plate-
let adhesion by 27.6±2.1% (n=8), similar to the increase observed
with Fibrogammin-P (33±6.7%, Fig. 4; n=19; p=0.8). This ﬁnding
suggests that transglutaminase activity of FXIII does not mediate in-
creased platelet adhesion to ﬁbrinogen.
Discussion
The involvement of FXIII transglutaminase activity in platelet spread-
ing was suggested by previous ﬁndings that monodansylcadaverine, in
the absence of added FXIII, diminished ﬁlopodia formation of normalFig. 2. Enhanced platelet adhesion to ﬁbrinogen following in vitro addition of FXIIIA2B2 or
FXIIIA2. Washed platelets obtained from the patients prior to treatment or from normal
control subjects were incubated on ﬁbrinogen-covered surface in the presence or absence
of 10 IU/mL of either Fibrogammin-P (FXIIIA2B2) or rFXIII (FXIIIA2). Bound platelets were
counted bymicroscopy. Each experiment was performed in quadruplicate. The results are
expressed asmean±SEMpercent platelet adhesion in the presence of added FXIII relative
to the adhesion observed before addition of FXIII.platelets on ﬁbrinogen [9] and that clot retraction in mice was inhibited
by the FXIII transglutaminase inhibitor, cystamine [7]. Given our earlier
ﬁnding that FXIIIA has PDI activity which is independent of its
transglutaminase activity [10], we examined the relative roles of
the two activities in platelet adhesion to ﬁbrinogen.
We show, for the ﬁrst time, that in patients with hereditary FXIIIA
deﬁciency, treatment with FXIIIA2B2 (Fibrogammin-P) increases platelet
adhesion toﬁbrinogen by almost 30% (Fig. 1). Theseﬁndings are in accor-
dance with previous reports that platelets from FXIII-deﬁcient patients
exhibit reduced adhesion to ﬁbrinogen in vitro [9]. Furthermore, the in
vitro addition of unactivated FXIIIA2B2 (Fibrogammin-P) or unactivated
FXIIIA2 (rFXIIIA), neither of which exhibits transglutaminase activity, to
either the patient or control platelets, enhanced platelet adhesion to
ﬁbrinogen (Fig. 2), suggesting that transglutaminase activity is not neces-
sary for platelet adhesion to ﬁbrinogen. This conclusion was further
supported by our ﬁnding that adhesion of the patients' platelets to ﬁbrin-
ogen in the presence of FXIII treated with iodoacetamide, in which
transglutaminase activity is blocked, was indistinguishable from that of
the patient's platelets in the presence of unactivated FXIII (Fig. 4). Thus,
in our hands transglutaminase activity did not mediate the enhanced
adhesion of platelets to ﬁbrinogen.
Our earlier work showed that unactivated FXIIIA2B2, I-FXIII, and
rFXIIIA2 all have similar PDI activity [10], pointing to a possible roleFig. 4. Enhanced platelet adhesion in the presence of I-FXIII and reduced platelet adhe-
sion by anti-FXIII antibody. Washed platelets obtained from the patients before treat-
ment were incubated on ﬁbrinogen-covered surface in the presence or absence of
either 10 IU/mL I-FXIII or anti-FXIIIA antibody at 1:20 dilution. Bound platelets were
counted by microscopy. Each experiment was performed in quadruplicate. Results
are expressed as mean±SEM percent platelet adhesion in the presence of I-FXIII
(n=8) or anti-FXIII antibody relative to their absence.
341J. Lahav et al. / Thrombosis Research 131 (2013) 338–341for FXIII PDI in platelet adhesion. Accordingly, in the present study, the
addition of rabbit anti-FXIIIA antibody that interfereswith FXIIIA PDI ac-
tivity but not FXIIIA transglutaminase activity (Fig. 3) reduced the adhe-
sion of the platelets in the presence of FXIII concentrate (Fig. 4), while
sheep anti-FXIIIA2B2 antibody that does not interfere with PDI activity
had no effect on adhesion. Moreover, the anti-PDI activity of rabbit anti
FXIIA antibody reduced the adhesion of untreated platelets, probably by
inhibiting surface-associated PDI on the platelets which is required for
intact platelet adhesion (11, 12).
By contrast, Jayo et al. [9] and Kasahara et al. [7] reported
that monodansylcadaverine and cystamine, competitive donors for
transglutaminase, inhibited FXIII-mediated adhesion. The reason for
the discrepancy from our study is not clear. If it stems from differ-
ences in the experimental procedures, it is possible that both the
transglutaminase and PDI activities of FXIII support platelet adhesion
to ﬁbrinogen in an additive manner. Alternatively, it is possible that
the inhibitors used to block transglutaminase activity in the earlier
studies [7,9] were not speciﬁc. Both monodansylcadaverine and
cystamine may block other thiol-dependent enzymes, particularly
calmudulin [21]. Indeed, one study showed that caspase-3 is inhibited
by cystamine [22]. Cystamine forms mixed disulﬁdes with PDI, and in
the cellular setting, it might inhibit the PDI activity of FXIII as well as
its transglutaminase activity. Our use of an antibody that speciﬁcally
blocks only the PDI activity of FXIII is a more direct means to address
this question.
Recently, researchers found that platelets adhered to FXIII-covered
surface independently of FXIII transglutaminase or PDI activity [6].
The independence of transglutaminase activity is in line with our previ-
ous results [10] and the results of the present study. These data also con-
ﬁrm our previous observation that FXIII can bind directly to platelets
[23]. However, in another study, we showed that PDI-dependent plate-
let adhesion is speciﬁc to platelet integrin-mediated adhesion [12,13].
Thus, the addition of FXIII following established platelet integrin–ﬁbrin-
ogen interaction, as in the present work, leaves FXIIIA PDI activity free
to enhance this interaction.
The increase in platelet adhesion elicited by unactivated FXIIIA2B2
or rFXIIIA2, as well as by I-FXIII, and the inhibition of adhesion by PDI-
blocking antibody, supports the hypothesis that the enhancement of
platelet adhesion associated with FXIII is mediated by its PDI activity.
This may have important therapeutic implications for the use of FXIII
concentrates. In addition to their well-established effect on secondary
hemostasis (clot stability), FXIII concentrates might also enhance pri-
mary hemostasis (platelet function) in patients with hereditary FXIIIA
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